New search | Conferencedetail
Print view

Triple Negative Breast Cancer Drug Development Summit

Evvnt Promotion / evvnt
28.04.2021 - 29.04.2021  Virtual
Time: 08:00 to 16:00
Conference themes
This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.

Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.
Professional congress organizer (PCO)
Hanson Wade

Speakers: Alison L. Hannah, Senior Vice President and Chief Medical Officer, CytomX Therapeutics, Angus Sinclair, VP Immuno-Oncology, IGM Biosciences, and more.

Enquiries and Registration:
Mr. Customer Services
Congress fees
Conference Only (Drug Developer Pricing): USD 1999.00, Conference Only (Service Provider Pricing): USD 2499.00, Conference Only (Academic Pricing): USD 1799.00
Participants expected
1000 - 1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Alumni Club Medizinische Universität WienEuropean Public Health Association (EUPHA)Charité International AcademyCenter of ExcellenceÖsterreichische Gesellschaft für Public HealthÄrzte der WeltSwiss Tropical and Public Health InstituteÖsterreichische Akademie der Ärzte